High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

 

Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers.

Market Dynamics

R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market. For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Increasing investment in R&D is expected to offer lucrative growth opportunities for players in the Anti-body Coupled T Receptor Therapy Market. For instance, in February 2021, Arcus Biosciences, Inc. received US$ 220 million to support and accelerate the company’s clinical development plans from Gilead Sciences, Inc., a U.S-based biopharmaceutical company, as the later increased its ownership in Arcus to 19.5%. Moreover, increasing number of clinical trials in antibody-coupled T receptor therapy is also expected to aid in growth of the market. For instance, in January 2020, Unum Therapeutics Inc. completed Cohort 1 enrollment with no dose-limiting toxiticies observed in the ATTCK-34-01 Phase 1 trial evaluating the company’s ACTR707, an antibody-coupled T cell receptor investigational therapy, together with trastuzumab for the treatment of patients with HER2+ advanced cancers.

The Anti-body Coupled T Receptor Therapy Market is witnessing several M&A activities. For instance, in July 2020, Cogent Biosciences (Unum Therapeutics) acquired Kiq LLC, a privately held, biotechnology company.

 Competitive Analysis

Major players operating in the Anti-body Coupled T Receptor Therapy Market include, Cogent Biosciences (Unum Therapeutics), Arcus Biosciences, Inc., and Seattle Genetics, Inc.

Major players operating in the Anti-body Coupled T Receptor Therapy Market are focused on R&D to expand their product portfolio. For instance, in 2018, Cogent Biosciences (Unum Therapeutics) received the U.S. patent design and use of the chimeric Antibody-Coupled T-cell Receptor (ACTR) platform technology for the  treatment of non-Hodgkin lymphoma, multiple myeloma, and HER2+ advanced cancers.